Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice.

The antiobesity and antidiabetic effects of the beta3-adrenergic agonists were investigated on nonobese type 2 diabetic MKR mice after injection with a beta3-adrenergic agonist, CL-316243. An intact response to acute CL-316243 treatment was observed in MKR mice. Chronic intraperitoneal CL-316243 treatment of MKR mice reduced blood glucose and serum insulin levels. Hyperinsulinemic euglycemic clamps exhibited improvement of the whole body insulin sensitivity and glucose homeostasis concurrently with enhanced insulin action in liver and adipose tissue. Treating MKR mice with CL-316243 significantly lowered serum and hepatic lipid levels, in part due to increased whole body triglyceride clearance and fatty acid oxidation in adipocytes. A significant reduction in total body fat content and epididymal fat weight was observed along with enhanced metabolic rate in both wild-type and MKR mice after treatment. These data demonstrate that beta3-adrenergic activation improves the diabetic state of nonobese diabetic MKR mice by potentiation of free fatty acid oxidation by adipose tissue, suggesting a potential therapeutic role for beta3-adrenergic agonists in nonobese diabetic subjects.

[1]  T. Homma,et al.  DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a beta3-adrenoceptor agonist, KTO-7924. , 2005, Pharmacological research.

[2]  O. Gavrilova,et al.  Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes , 2004, Diabetologia.

[3]  S. Collins,et al.  Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. , 2004, Molecular endocrinology.

[4]  M. Reitman,et al.  Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. , 2003, Diabetes.

[5]  M. Reitman,et al.  Opposite Effects of Background Genotype on Muscle and Liver Insulin Sensitivity of Lipoatrophic Mice , 2003, The Journal of Biological Chemistry.

[6]  J. Arch.  β3-Adrenoceptor agonists: potential, pitfalls and progress , 2002 .

[7]  G. Shulman,et al.  Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. , 2001, Genes & development.

[8]  A. Martí,et al.  Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist. , 2001, Biochemical pharmacology.

[9]  M. Donath,et al.  beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. , 2001, Diabetes.

[10]  O. Gavrilova,et al.  Lack of responses to a beta3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. , 2000, Diabetes.

[11]  F. Milagro,et al.  Effects of the Oral Administration of a β3‐Adrenergic Agonist on Lipid Metabolism in Alloxan‐Diabetic Rats , 2000 .

[12]  C. Kahn,et al.  Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. , 2000, The Journal of clinical investigation.

[13]  A. Martí,et al.  Up-regulation of muscle UCP2 gene expression by a new β3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals , 2000, International Journal of Obesity.

[14]  A. Bonen,et al.  Muscle-specific Overexpression of FAT/CD36 Enhances Fatty Acid Oxidation by Contracting Muscle, Reduces Plasma Triglycerides and Fatty Acids, and Increases Plasma Glucose and Insulin* , 1999, The Journal of Biological Chemistry.

[15]  James H. Brown,et al.  The fourth dimension of life: fractal geometry and allometric scaling of organisms. , 1999, Science.

[16]  H. Yoshitomi,et al.  Differential regulation of mouse uncoupling proteins among brown adipose tissue, white adipose tissue, and skeletal muscle in chronic beta 3 adrenergic receptor agonist treatment. , 1998, Biochemical and biophysical research communications.

[17]  E. Ravussin,et al.  Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. , 1998, Diabetes.

[18]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[19]  R. Huupponen,et al.  Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism. , 1997, European journal of pharmacology.

[20]  E. Horton,et al.  CL-316,243, a β3-Specific Adrenoceptor Agonist, Enhances Insulin-Stimulated Glucose Disposal in Nonobese Rats , 1997, Diabetes.

[21]  B. Lowell,et al.  β3-Adrenergic Receptors on White and Brown Adipocytes Mediate β3-Selective Agonist-induced Effects on Energy Expenditure, Insulin Secretion, and Food Intake , 1997, The Journal of Biological Chemistry.

[22]  J. Himms-Hagen,et al.  Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist. , 1997, Biochemical pharmacology.

[23]  M. Prentki,et al.  Long-Chain Fatty Acids Inhibit Acetyl-CoA Carboxylase Gene Expression in the Pancreatic β-Cell Line INS-1 , 1997, Diabetes.

[24]  K. Kumamoto,et al.  Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. , 1996, The Journal of clinical investigation.

[25]  C. Charon,et al.  Effect of the beta-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats. , 1995, The American journal of physiology.

[26]  R. Fremeau,et al.  Distribution of β3-adrenoceptor mRNA in human tissues , 1995 .

[27]  C. Arbeeny,et al.  Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice. , 1995, The American journal of physiology.

[28]  B. Lowell,et al.  The potential significance of beta 3 adrenergic receptors. , 1995, The Journal of clinical investigation.

[29]  M. Stock,et al.  Acute effects of the β3‐adrenoceptor agonist, BRL 35135, on tissue glucose utilisation , 1995, British journal of pharmacology.

[30]  N. Sakane,et al.  Anti-obesity effect of CL 316,243, a highly specific beta 3-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. , 1994, European journal of endocrinology.

[31]  J. Himms-Hagen,et al.  Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats. , 1994, The American journal of physiology.

[32]  T. Gettys,et al.  Impaired expression and functional activity of the beta 3- and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. , 1994, Molecular endocrinology.

[33]  J. Arch,et al.  β3 and Atypical β‐Adrenoceptors , 1993 .

[34]  M. Dutia,et al.  Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. , 1992, Journal of medicinal chemistry.

[35]  H. Kaslow,et al.  Radiometric assays for glycerol, glucose, and glycogen. , 1989, Analytical biochemistry.

[36]  J. MacLeod,et al.  Repetitive blood sampling in unrestrained and unstressed mice using a chronic indwelling right atrial catheterization apparatus. , 1988, Laboratory animal science.

[37]  P. Moe,et al.  Animal and Human Calorimetry , 1988 .

[38]  J. A. McLean,et al.  Animal and human calorimetry: Preface , 1988 .

[39]  M. Cawthorne,et al.  Brown adipose tissue is a major site of glucose utilisation in C57B16obob mice treated with a thermogenic β-adrenoceptor agonist , 1985 .

[40]  M. Sennitt,et al.  Effects of BRL 26830, a novel beta-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats. , 1985, Biochemical pharmacology.

[41]  W. Wilfinger,et al.  Fluorometric quantification of DNA in cells and tissue. , 1983, Analytical biochemistry.

[42]  M. Rodbell.  METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. , 1964, The Journal of biological chemistry.

[43]  J. Arch.  beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. , 2002, European journal of pharmacology.

[44]  T. Kadowaki,et al.  Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model. , 2001, Diabetes.

[45]  J. Martínez,et al.  Effects of the oral administration of a beta3-adrenergic agonist on lipid metabolism in alloxan-diabetic rats. , 2000, The Journal of pharmacy and pharmacology.

[46]  F. Cambien,et al.  Polymorphism of the human beta3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. , 1999, Diabetes.

[47]  N. Sakane,et al.  Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes. , 1999, Diabetes.

[48]  B. Lowell,et al.  Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. , 1997, The Journal of biological chemistry.

[49]  R. Fremeau,et al.  Distribution of beta 3-adrenoceptor mRNA in human tissues. , 1995, European journal of pharmacology.

[50]  J. Arch,et al.  Beta 3 and atypical beta-adrenoceptors. , 1993, Medicinal research reviews.

[51]  F. Lönnqvist,et al.  Tissue distribution of beta 3-adrenergic receptor mRNA in man. , 1993, The Journal of clinical investigation.

[52]  M. Cawthorne,et al.  Brown adipose tissue is a major site of glucose utilisation in C57Bl/6 ob/ob mice treated with a thermogenic beta-adrenoceptor agonist. , 1985, Biochemical and biophysical research communications.